Early Response Predicts Later Response to Olanzapine in Schizophrenia
Author Information
Author(s): Haya Ascher-Svanum, Fangyi Zhao, Holland C Detke, Allen W Nyhuis, Anthony H Lawson, Virginia L Stauffer, William Montgomery, Michael M Witte, David P McDonnell
Primary Institution: Eli Lilly and Company
Hypothesis
Does early response to olanzapine long-acting injection predict later response in patients with schizophrenia?
Conclusion
Early response to olanzapine LAI predicts better clinical and functional outcomes in patients with schizophrenia.
Supporting Evidence
- Early response predicted later response with high sensitivity (85%) and specificity (72%).
- Early Responders had significantly greater improvement in PANSS scores at all time points.
- 20% of Early Non-responders showed response by Week 8.
Takeaway
If patients with schizophrenia start feeling better within the first month of treatment, they are likely to keep improving.
Methodology
This was an 8-week, randomized, double-blind, placebo-controlled trial assessing olanzapine LAI in patients with schizophrenia.
Limitations
Results may not apply to less severe cases or longer treatment periods, and the PANSS measure used is lengthy for clinical practice.
Participant Demographics
The majority of participants were white, approximately one-third were female, and the average age was close to 40 years.
Statistical Information
P-Value
p < .01
Statistical Significance
p ≤ .01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website